Symbols

PHIO

Phio Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PHIO

Phio Pharmaceuticals Corp.

A clinical stage biotechnology company that develops therapeutics based on RNA interference

Industry

Pharmaceutical

Established Date

09/08/2011

Listing Date

02/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.phiopharma.com

Security Type

Common stock

Office address

411 Swedeland Road Suite 23-1080 King of Prussia PA 19406

Business

Introduction

Phio Pharmaceuticals Corp. was incorporated in Delaware on September 8, 2011. Phio is a clinical-stage biopharmaceutical company that utilizes its proprietary INTASYL small interfering RNA gene silencing technology to enhance the effectiveness of immune cells to target and destroy tumor cells. The company is committed to developing therapies that use INTASYL technology to specifically target proteins that inhibit the body's anti-cancer ability, without relying on special preparations or drug delivery systems. Dedicated to the discovery and development of innovative cancer therapies, Phio Pharmaceuticals aims to open new avenues to a cancer-free future. The company adopts the model of a single operating department and a single reporting department.

Company Financials

EPS

PHIO has released its 2025 Q2 earnings. EPS was reported at -0.45, versus the expected -0.36, missing expectations. The chart below visualizes how PHIO has performed over recent quarters, highlighting trends in earnings surprises.